0001213900-22-070211 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2022	Nov. 08, 2022
Document Information Line Items
Entity Registrant Name	SeqLL, Inc.
Trading Symbol	SQL
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		11,886,379
Amendment Flag	false
Entity Central Index Key	0001605888
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-150332
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5319744
Entity Address, Address Line One	3 Federal Street
Entity Address, City or Town	Billerica
Entity Address, Country	MA
Entity Address, Postal Zip Code	01821
City Area Code	(781)
Local Phone Number	460-6016
Title of 12(b) Security	Common Stock, par value $.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 4,453,521	$ 4,015,128
Marketable securities	2,499,685	5,933,364
Accounts receivable, net of allowance for doubtful accounts of $6,016	29,514	30,714
Other receivables	60,000	34,965
Inventory	246,904	224,155
Prepaid expenses	222,831	186,056
Total current assets	7,512,455	10,424,382
Other assets
Property and equipment, net	548,966	265,267
Operating lease right-of-use asset	1,161,743
Other assets	127,759	50,488
Total assets	9,350,923	10,740,137
Current liabilities
Accounts payable	583,573	871,364
Accrued expenses	304,101	311,405
Non-convertible promissory notes - current		1,375,000
Current portion of operating lease liability	83,145
Total current liabilities	970,819	2,557,769
Non-current liabilities
Operating lease liability, less current portion	1,491,649
Non-convertible promissory notes - long-term	1,375,000
Total liabilities	3,837,468	2,557,769
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.00001 par value; 80,000,000 shares authorized; 11,886,379 shares issued and outstanding	119	119
Additional paid-in capital	22,786,005	22,596,100
Accumulated deficit	(17,272,669)	(14,413,851)
Total stockholders’ equity	5,513,455	8,182,368
Total liabilities and stockholders’ equity	$ 9,350,923	$ 10,740,137

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, net of allowances for doubtful accounts (in Dollars)	$ 6,016	$ 6,016
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	11,886,379	11,886,379
Common stock, shares outstanding	11,886,379	11,886,379

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Sales		$ 15,937	$ 1,177	$ 48,021
Grant revenue		34,964	77,482	127,009
Total revenue		50,901	78,659	175,030
Cost of sales		4,049	690	44,792
Gross profit		46,852	77,969	130,238
Operating expenses
Research and development	$ 428,771	90,658	1,129,286	133,074
General and administrative	489,729	360,944	1,700,340	1,173,565
Total operating expenses	918,500	451,602	2,829,626	1,306,639
Operating loss	(918,500)	(404,750)	(2,751,657)	(1,176,401)
Other (income) and expenses
Unrealized loss (gain) on marketable securities	242		(54,266)
Realized loss on marketable securities			106,324
Interest and other income	(9,981)	(93)	(18,457)	(190,193)
Change in fair value of convertible notes		193,776		195,962
Loss on extinguishment of convertible notes				934,257
Interest expense	17,188	41,066	73,560	189,993
Net loss	$ (925,949)	$ (639,499)	$ (2,858,818)	$ (2,306,420)
Net loss per share - basic and diluted (in Dollars per share)	$ (0.08)	$ (0.09)	$ (0.24)	$ (0.41)
Weighted average common shares - basic and diluted (in Shares)	11,886,379	7,171,232	11,886,379	5,642,100

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net loss per share - basic and diluted (in Dollars per share)	$ (0.08)	$ (0.09)	$ (0.24)	$ (0.41)
Weighted average common shares - basic and diluted (in Shares)	11,886,379	7,171,232	11,886,379	5,642,100

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 58	$ 49	$ 6,856,020	$ (10,710,293)	$ (3,854,166)
Balance (in Shares) at Dec. 31, 2020	5,791,665	4,864,862
Stock-based compensation expense			1,007		1,007
Net loss				(1,414,618)	(1,414,618)
Balance at Mar. 31, 2021	$ 58	$ 49	6,857,027	(12,124,911)	(5,267,777)
Balance (in Shares) at Mar. 31, 2021	5,791,665	4,864,862
Balance at Dec. 31, 2020	$ 58	$ 49	6,856,020	(10,710,293)	(3,854,166)
Balance (in Shares) at Dec. 31, 2020	5,791,665	4,864,862
Net loss					(2,306,420)
Balance at Sep. 30, 2021		$ 119	22,481,066	(13,016,713)	9,464,472
Balance (in Shares) at Sep. 30, 2021		11,886,379
Balance at Mar. 31, 2021	$ 58	$ 49	6,857,027	(12,124,911)	(5,267,777)
Balance (in Shares) at Mar. 31, 2021	5,791,665	4,864,862
Stock-based compensation expense			3,192		3,192
Net loss				(252,303)	(252,303)
Balance at Jun. 30, 2021	$ 58	$ 49	6,860,219	(12,377,214)	(5,516,888)
Balance (in Shares) at Jun. 30, 2021	5,791,665	4,864,862
Stock-based compensation expense			214,745		214,745
Conversion of preferred stock into common stock	$ (58)	$ 31	27
Conversion of preferred stock into common stock (in Shares)	(5,791,665)	3,130,622
Conversion of convertible notes into common stock		$ 6	3,222,300		3,222,306
Conversion of convertible notes into common stock (in Shares)		641,895
Issuance of Units and warrants to underwriters in initial public offering, net of issuance costs of $1,555,976		$ 31	11,453,614		11,453,645
Issuance of Units and warrants to underwriters in initial public offering, net of issuance costs of $1,555,976 (in Shares)		3,060,000
Issuance of common stock to underwriters in initial public offering, net of issuance costs of $71,199		$ 2	730,161		730,163
Issuance of common stock to underwriters in initial public offering, net of issuance costs of $71,199 (in Shares)		189,000
Net loss				(639,499)	(639,499)
Balance at Sep. 30, 2021		$ 119	22,481,066	(13,016,713)	9,464,472
Balance (in Shares) at Sep. 30, 2021		11,886,379
Balance at Dec. 31, 2021		$ 119	22,596,100	(14,413,851)	8,182,368
Balance (in Shares) at Dec. 31, 2021		11,886,379
Stock-based compensation expense			55,914		55,914
Net loss				(937,954)	(937,954)
Balance at Mar. 31, 2022		$ 119	22,652,014	(15,351,805)	7,300,328
Balance (in Shares) at Mar. 31, 2022		11,886,379
Balance at Dec. 31, 2021		$ 119	22,596,100	(14,413,851)	8,182,368
Balance (in Shares) at Dec. 31, 2021		11,886,379
Net loss					(2,858,818)
Balance at Sep. 30, 2022		$ 119	22,786,005	(17,272,669)	5,513,455
Balance (in Shares) at Sep. 30, 2022		11,886,379
Balance at Mar. 31, 2022		$ 119	22,652,014	(15,351,805)	7,300,328
Balance (in Shares) at Mar. 31, 2022		11,886,379
Stock-based compensation expense			66,995		66,995
Net loss				(994,915)	(994,915)
Balance at Jun. 30, 2022		$ 119	22,719,009	(16,346,720)	6,372,408
Balance (in Shares) at Jun. 30, 2022		11,886,379
Stock-based compensation expense			66,996		66,996
Net loss				(925,949)	(925,949)
Balance at Sep. 30, 2022		$ 119	$ 22,786,005	$ (17,272,669)	$ 5,513,455
Balance (in Shares) at Sep. 30, 2022		11,886,379

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) (Parentheticals)	3 Months Ended
	Sep. 30, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance cost	$ 1,555,976
Issuance of common stock	$ 71,199

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net loss	$ (2,858,818)	$ (2,306,420)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation	58,718	64,543
Unrealized gain on marketable securities	(54,266)
Realized loss on marketable securities	106,324
Loss on extinguishment of notes		934,257
Stock-based compensation	189,905	218,944
Change in fair value of convertible notes		195,962
Non-cash lease expense	100,291
Changes in operating assets and liabilities:
Accounts receivable, net	1,200	(25)
Other receivables	(25,035)	73,851
Prepaid expenses	(36,775)	(270,150)
Inventory	(22,749)	(5,704)
Other assets	(77,271)
Accounts payable	(287,791)	(94,674)
Accrued expenses	(7,304)	166,445
Net cash used in operating activities	(2,913,571)	(1,022,971)
Cash Flows from Investing Activities
Purchases of lab equipment	(29,657)	(5,250)
Purchases of marketable securities	(2,500,517)
Sales of marketable securities	5,882,138
Net cash provided by (used in) investing activities	3,351,964	(5,250)
Cash Flows from Financing Activities
Proceeds from issuance of units, gross		13,009,621
Proceeds from issuance of common stock to underwriters, gross		801,362
Payment for issuance costs of units and common stock		(1,558,193)
Proceeds from issuance of convertible notes		250,000
Settlement of convertible notes		(141,884)
Proceeds from loan payable – related party		140,000
Payment of loan payable – related party		(166,000)
Net cash provided by financing activities		12,334,906
Net increase (decrease) in cash and cash equivalents	438,393	11,306,685
Cash and cash equivalents, beginning of period	4,015,128
Cash and cash equivalents, end of period	4,453,521	11,306,685
Non-cash investing activities
Right-of-use asset acquired through operating lease	1,257,495
Leasehold improvements financed through tenant improvement allowance	312,760
Conversion of notes at initial public offering into common stock		3,222,206
Issuance costs in accounts payable		68,982
Fair value of warrants for common stock issued to underwriters		1,647,076
Conversion of preferred stock par value to common stock and additional paid-in capital		$ 58

Nature of Operations and Basis of Presentation

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Nature of Operations and Basis of Presentation

Note 1 – Nature of Operations and Basis of Presentation

SeqLL Inc. was incorporated as a Delaware corporation on April 3, 2014. On April 8, 2014, SeqLL Inc. acquired a 100% ownership interest in SeqLL, LLC (“Subsidiary”), a domestic limited liability company formed on March 11, 2013 in the State of Massachusetts. SeqLL Inc. is a holding company of the Subsidiary (together the “Company” or “SeqLL”) and is a life sciences company focused on the development and application of innovative genetic analysis technologies and the monetization of that technology and related intellectual property. The Subsidiary owns technology to enable the analysis of large volumes of genetic material by directly sequencing single molecules of DNA or RNA. The Subsidiary’s principal office is located in Billerica, Massachusetts.

Initial Public Offering

On August 31, 2021, the Company completed its initial public offering (“IPO”) whereby it sold 3,060,000 units, each unit consisting of one share of the Company’s common stock and a warrant to purchase one share of common stock at an exercise price of $4.25 per share (the “Warrants”), at a price to the public of $4.25 per unit. The gross proceeds from the IPO were approximately $13 million and were offset by $3.2 million in offering costs, of which $1.6 million was paid in cash and $1.6 million was issued in warrants to Maxim Group LLC (“Underwriter”) (see Note 8). In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically converted into 3,130,622 shares of common stock (see Note 9). Additionally, the outstanding convertible notes converted into 641,895 shares of common stock (see Note 7).

Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 45-day option to purchase up to 459,000 additional shares of common stock, and/or 459,000 additional Warrants, to cover over-allotments in connection with the Offering. The Underwriter partially exercised this option and purchased 459,000 Warrants on August 31, 2021, at $0.01 per Warrant. On September 29, 2021, the Company issued 189,000 shares of common stock to the underwriters at a price of $4.24 per share from the exercise of the overallotment option, raising the net proceeds of approximately $730,000, net of offering costs.

Notice from the Nasdaq Stock Market

On June 21, 2022, SeqLL received notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for its common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the $1.00 minimum bid price requirement for continued listing.

The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock or its warrants to purchase common stock under the symbols “SQL” and “SQLLW,” respectively. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days.

If the Company does not regain compliance by December 18, 2022, the Company may be eligible for an additional grace period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period. If the Company meets these requirements, the Nasdaq staff will grant an additional 180 calendar days for the Company to regain compliance with the minimum bid price requirement. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process.

Risks and Uncertainties

The Company is subject to a number of risks similar to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.

Results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond the Company’s control. The Company’s business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact the Company’s business.

Basis of Presentation

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, SeqLL, LLC. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2022 and its results of operations for the three- and nine-months ended September 30, 2022 and 2021, and changes in shareholders’ equity and cash flows for the periods presented. The results disclosed in the condensed consolidated statements of operations for the three- and nine-months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 filed with the Securities and Exchange Commission.

Significant Accounting Policies

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Significant Accounting Policies

Note 2 – Significant Accounting Policies

During the nine-month period ended September 30, 2022, there were no changes to the significant accounting policies in relation to what was described in the Annual Report on Form 10-K for the year ended December 31, 2021, other than the items noted in the Recently Adopted Accounting Standards section below.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include but are not limited to stock-based compensation expense and research and development accruals. Actual results could differ from those estimates and changes in estimates may occur.

Investments in marketable securities

The Company accounts for its investments in debt securities in accordance with Accounting Standards Codification (“ASC”) 320, Investments — Debt Securities (“ASC 320”). Debt securities, which are comprised of investments in U.S. Treasury Securities, are measured at fair value, based on quoted market prices. As the Company has classified its investments in debt securities as available-for-sale, the Company recognizes all unrealized gains and losses in other comprehensive income, net of tax, and recognizes all realized gains and losses in the Company’s statement of operations.

The Company accounts for its investments in equity securities in accordance with ASC 321, Investments — Equity Securities (“ASC 321”). Equity securities, which are comprised of investments in mutual funds shares, are measured at fair value, based on quoted market prices, with all gains and losses reported in the Company’s statement of operations.

The Company may sell its debt or equity securities in response to changes in interest rates, risk/reward characteristics, liquidity needs or other factors.

Inventory

Inventory consists of finished goods, work-in-process and raw materials and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”) method. As the Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory. The Company evaluates the carrying cost of finished goods, work-in-process and raw materials items. To the extent that such costs exceed future demand estimates and /or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the applicable inventories. Inventory consisted of the following:

	September 30,		December 31,
	2022		2021

Raw materials	$	118,216	$	91,995
Work in process		128,688		132,160
Total inventory	$	246,904	$	224,155

Stock-based Compensation

The Company’s share-based compensation program grant awards include stock options and restricted stock awards to employees, directors and consultants. The fair value of stock option grants is estimated as of the date of the grant using the Black-Scholes option pricing model. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant. The fair value of the stock-based awards is then expensed over the requisite service period, generally the vesting period, for each award.

The Company’s expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the life of the option. No dividend yield was assumed as the Company does not pay dividends on its common stock. The Company recognizes forfeitures related to stock-based awards as they occur.

The Company has periodically granted stock options and restricted stock awards to consultants for services, pursuant to the Company’s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be cancelled. For awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards, which is generally the period services are rendered by such consultants and non-employees.

The assumptions used in determining the fair value of share-based awards granted during the nine-months ended September 30, 2022 are as follows:

	September 30, 2022
Risk-free interest rate		1.64	%
Expected option life		6 – 6.1 years
Expected dividend yield		0	%
Expected stock price volatility		54	%

Segments

The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies.

Leases

In the first quarter of 2022, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) . The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company recognizes right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company’s incremental borrowing rate and amortizing over the remaining terms of the leases. The Company accounts for the leases of less than 12 months as short-term leases. See the Recently Adopted Accounting Standards below for additional information related to the adoption of this accounting standard.

Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:

	September 30,
	2022		2021
Stock options		2,003,919		818,915
Warrants for common stock		4,388,185		4,393,396

Recently Adopted Accounting Standards

In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard on January 1, 2022, which had no material impact to the Company’s condensed consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”) which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to the Company’s condensed consolidated financial statements.

Recently Issued Accounting Standards

The Company does not believe that other recently issued but not yet effective accounting pronouncements are expected to have a material effect on the Company’s condensed consolidated financial statements.

Accrued Expenses

9 Months Ended

Sep. 30, 2022

Accrued Liabilities And Other Liabilities [Abstract]

Accrued Expenses

Note 3 – Accrued Expenses

Accrued expenses consisted of the following:

	September 30,		December 31,
	2022		2021

Accrued interest	$	289,633	$	216,073
Other		14,468		95,332
	$	304,101	$	311,405

Fair Value Measurements

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4 – Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and requires disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1:

Observable inputs such as quoted prices in active markets.

Level 2:

Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

Level 3:

Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

As of September 30, 2022, the Company had $4,002,061 of investments in U.S. Treasury Securities, of which $1,502,376 was included in cash and cash equivalents. The fair value of these investments was determined with Level 1 inputs through references to quoted market prices.

As of December 31, 2021, the Company had $5,993,385 of investments in mutual funds, of which $60,021 was included in cash and cash equivalents. The fair value of these investments was determined with Level 1 inputs through references to quoted market prices.

There were no liabilities measured at fair value at September 30, 2022 or December 31, 2021.

The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis for the nine-month period ended September 30, 2021.

	Convertible Notes
Balance at December 31, 2020	$	-
Issuance of Amended Notes		3,168,236
Change in fair value of convertible notes		195,962
Fair value of convertible notes at IPO date		(3,364,198	)
Balance at September 30, 2021	$	-

At the IPO date, the Amended Notes (as defined in Note 7) were converted into 641,895 shares of common stock (see Note 7). The interest expense of $89,239 for the period between the date of the Conversion Agreements related to the Amended Notes (see Note 7) and September 30, 2021 was included in the change in fair value of the Amended Notes.

There were no assets or liabilities measured at fair value on a non-recurring basis during the three- and nine- months ended September 30, 2022 or 2021.

The carrying values of financial instruments such as accounts receivable, net, other receivables, accounts payable, and accrued expenses approximated fair value as of September 30, 2022 and December 31, 2021 due to their short-term maturities.

The carrying value of the Company’s Non-Convertible Promissory Note approximated its fair value as of September 30, 2022 and December 31, 2021.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stock Option Plan

9 Months Ended

Sep. 30, 2022

Stock Option Plan [Abstract]

Stock Option Plan

Note 5 – Stock Option Plan

The Company’s 2014 Equity Incentive Plan (the “2014 Plan”) permits the grant of options for its common stock and shares of common stock to its employees, board members and consultants for up to 3,500,000 shares.

As of September 30, 2022, there were 1,496,081 shares available for future issuance under the 2014 Plan. Generally, option awards are granted with an exercise price equal to the fair value of the Company’s stock at the date of grant and vest over a period of three to four years. No option may have a term in excess of ten years from the option grant date. Certain option and share awards provide for accelerated vesting if there is a change in control (as defined by the 2014 Plan). The weighted average grant date fair value of options granted in the nine-month period ended September 30, 2022 was $0.89 per share. No option awards were granted during the nine months ended September 30, 2021.

The stock option activity for the period ended September 30, 2022 is as follows:

	Number of Options		Weighted- Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in Years)
Outstanding as of December 31, 2021		918,919	$	2.09		5.79
Granted		1,085,000	$	1.71
Outstanding of September 30, 2022		2,003,919	$	1.88		7.34
Exercisable at September 30, 2022		919,088	$	2.09		5.04

During the three months ended September 30, 2022 and 2021, the Company recorded $66,996 and $214,745, respectively, of stock-based compensation associated with vesting of stock options, of which $46,394 and $214,745 were included in general and administrative expenses for the three months ended September 30, 2022 and 2021, respectively, and $20,602 and $0 were included in research and development expenses for the three months ended September 30, 2022 and 2021, respectively.

During the nine months ended September 30, 2022 and 2021, the Company recorded $189,905 and $218,944, respectively, of stock-based compensation associated with vesting of stock options, of which $131,533 and $218,944 were included in general and administrative expenses for the nine months ended September 30, 2022 and 2021, respectively, and $58,372 and $0 were included in research and development expenses for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022, there was approximately $777,808 of unrecognized compensation expense related to unvested share-based compensation awards, which will be recognized over a weighted average period of approximately 1.62 years.

Related Party Transactions

9 Months Ended

Sep. 30, 2022

Related Party Transactions

Note 6 – Related Party Transactions

At September 30, 2022 and December 31, 2021, the Company had the following outstanding payables to its shareholders for past services, which are included within the Company’s accounts payable above:

	September 30, 2022		December 31, 2021

Genomic Diagnostic Technologies	$	-	$	23,725
St. Laurent Institute		232,418		313,679
St. Laurent Realty, Inc.		7,558		27,913
Total related party payables	$	239,976	$	365,317

The above entities are affiliated with (1) William C. St. Laurent, a former member of the Company’s board of directors, (2) relatives of Mr. St. Laurent or (3) entities controlled by the St. Laurent family, who are controlling shareholders of the Company. St. Laurent Realty, Inc. and Genomic Diagnostic Technologies assisted the Company by previously providing corporate accounting support; St. Laurent Institute, a non-for-profit company, provided bioinformatics specialist support for certain sequencing services.

Notes Payable

9 Months Ended

Sep. 30, 2022

Notes Payable [Abstract]

Notes Payable

Note 7 – Notes Payable

The Company entered into a series of convertible promissory notes (the “Convertible Notes”) through April 8, 2019, with certain preferred stockholders amounting to $905,000. The Convertible Notes had a one-year term and accrued interest at 10% per annum. The Convertible Notes were convertible at the lower of $3.10 per share or a 20% discount to the share price paid by the purchasers of equity securities in the Company’s next Qualified Financing, as defined in the convertible note agreement.

From April 29, 2019, to April 29, 2020, the Company entered into a series of non-convertible promissory notes (the “Promissory Notes”) with a certain preferred stockholder amounting to $1,375,000. The Promissory Notes had a one-year term with interest accruing at 10% per annum.

In November and December 2020, the Company issued senior secured convertible promissory notes to a third-party investor amounting to $200,000. These notes accrued interest at 10% per annum, were to be repaid at the earlier of December 31, 2022, or the Company’s next qualified financing of a minimum of $7.5 million (as defined in the notes agreement) and were convertible at $3.75 per share.

On December 31, 2020, the Company issued a non-convertible promissory note to St. Laurent Investments LLC amounting to $426,020 due July 31, 2022, bearing 10% interest per annum in exchange for the accrued interest on all its notes of the Company outstanding through that date.

From January to March 2021, the Company issued senior secured convertible promissory notes to investors for total proceeds of $250,000. The Convertible Notes accrued interest at 10% per annum, matured at the earlier of December 31, 2022, or the Company’s next qualified equity offering of a minimum of $7.5 million, and were convertible at $3.75 per share.

On February 3, 2021, the preferred stockholder and the holder of $2,910,710 in the Convertible Notes and Promissory Notes of the Company granted the Company an extension on all its notes of the Company to be repaid on or before July 31, 2022. This amendment was accounted for on a prospective basis under the troubled debt restructuring guidance.

In March 2021, the Company entered into a series of agreements with the noteholders to automatically convert $786,730 in outstanding Promissory Notes and $1,305,000 in Convertible Notes (together, “Amended Notes”), to common stock upon the closing of the IPO (“Conversion Agreements”), of which $1,552,683 was held by St. Laurent Investments, LLC and its affiliates. Under the terms of the conversion agreements, $826,020 and $1,265,710 in Amended Notes were to be converted at the closing of the IPO based on the $3.75 and $3.10 conversion prices, respectively. Since the automatic conversion could result in a material benefit to the noteholders, this amendment was deemed substantive and was accounted for as an extinguishment of debt. Accordingly, the Company recognized a loss on extinguishment of debt totaling $934,257 in the consolidated statement of operations for the three months ended March 2021, which represented the excess of the fair value of the Amended Notes totaling $3,118,235 over their carrying value of $2,183,978. The Company elected the option to account for the Amended Notes at fair value, with the changes in fair value recognized in the statement of operations. The fair value of the Amended Notes was estimated using probability weighted expected payouts under various settlement scenarios, discounted to their present value based on the estimated effective rate of return.

On April 29, 2021, the Company entered into an agreement with a noteholder to automatically convert an additional $50,000 in outstanding Amended Notes, including any accrued interest, to common stock upon the closing of the IPO at the conversion price of $3.75 per share.

At the IPO date, the Amended Notes automatically converted based on their original terms into 641,895 shares of common stock. The fair value of the Amended Notes of $3,364,198 immediately prior to the conversion, less a $141,884 cash payment related to the accrued interest, was reclassified into the additional paid in capital on the condensed consolidated balance sheet. The fair value of the Amended Notes at the conversion date was estimated based on the fair value of the common stock issued upon the conversion.

The Company recognized $195,962 loss due to the change in fair value of the Amended Notes between the amendment date and their conversion at the IPO date.

In October 2021, the Company entered into an agreement with St. Laurent Investments LLC to reduce the interest on $1,375,000 principal amount of the Promissory Notes from 10% to 5% per year starting on October 1, 2021. The Company accounted for this transaction as a modification on a prospective basis.

In October 2021, the Company repaid $270,000 of the Promissory Notes to William C. St Laurent in cash.

In connection with all the Convertible Notes and Promissory Notes issued during 2021 and 2020, the Company issued warrants to noteholders to purchase the total of 66,665 and 53,333 shares of the Company’s common stock, including 11,466 to the placement agent (see Note 8). The fair values of these warrants were immaterial at issuance.

In June 2022, the Company entered into an agreement with St. Laurent Investments LLC to extend the maturity date of the $1,375,000 Promissory Note to July 31, 2024. The Company accounted for this transaction as a modification on a prospective basis.

For the three months ended September 30, 2022 and 2021, interest expense was $17,188 and $41,066, respectively.

For the nine months ended September 30, 2022 and 2021, interest expense was $73,560 and $189,993, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Common Stock Warrants

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Common Stock Warrants

Note 8 – Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase the Company’s common stock as of September 30, 2022:

Issuance Date	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date
8/30/2018		3,088	$	3.10	8/29/2023
9/30/2018		60,506	$	3.10	9/29/2023
9/30/2018		486,486	$	2.16	9/29/2023
10/17/2018		1,157	$	3.10	10/16/2023
11/2/2018		964	$	3.10	11/1/2023
11/9/2018		964	$	3.10	11/8/2023
11/16/2018		964	$	3.10	11/15/2023
11/29/2018		964	$	3.10	11/28/2023
12/21/2018		964	$	3.10	12/20/2023
12/27/2018		964	$	3.10	12/26/2023
1/31/2019		1,930	$	3.10	1/30/2024
2/7/2019		1,640	$	3.10	2/6/2024
2/21/2019		1,640	$	3.10	2/20/2024
3/20/2019		3,378	$	3.10	3/18/2024
4/8/2019		1,930	$	3.10	4/6/2024
11/19/2020		53,333	$	4.10	6/30/2024
11/19/2020		8,533	$	4.10	6/30/2024
1/8/2021		13,333	$	4.10	6/30/2024
1/11/2021		26,666	$	4.10	6/30/2024
2/13/2021		13,333	$	4.10	6/30/2024
3/16/2021		10,665	$	4.10	6/30/2024
3/16/2021		13,333	$	4.10	6/30/2024
8/31/2021		3,519,000	$	4.25	8/31/2026
8/31/2021		153,000	$	4.675	8/26/2026
9/29/2021		9,450	$	4.675	8/26/2026
		4,388,185

During the nine-month period ended September 30, 2022, warrants to purchase 5,211 shares of common stock with an exercise price of $3.10 expired.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Preferred Stock

9 Months Ended

Sep. 30, 2022

Preferred Stock [Abstract]

Preferred Stock

Note 9 – Preferred Stock

The Company had outstanding preferred stock as of December 31, 2020:

	Shares authorized		Shares issued		Issuance price per share
Series A-1 Convertible Preferred Stock				3,125,000	$	0.32
Series A-2 Convertible Preferred Stock				2,666,665	$	1.68
Series A Preferred stock		20,000,000		5,791,665

The Series A-1 Preferred Stock (“Series A-1”) and Series A-2 Preferred Stock (“Series A-2”) collectively the Preferred Stock”, could be converted at any time at the election of the holder into common stock at an initial conversion price determined by dividing the Series A-1 original issue price of $0.59, as amended, by the Series A-1 conversion price of $0.59; and the Series A-2 original issue price of $3.10, as amended, by the Series A-2 conversion price of $3.10; both were subject to adjustment for stock splits, stock combinations and the like, and to a weighted-average adjustment for future issuances of common stock, warrants or rights to purchase common stock or securities convertible into common stock for a consideration per share that is less than the then-applicable conversion price, subject to certain exceptions listed in the Charter.

The Preferred Stock was subject to automatic conversion upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred Stock voting together as a single class.

In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock, upon the consent of the holders of a majority of the Preferred Stock, automatically converted into 3,130,622 shares of common stock.

Marketable Securities

9 Months Ended

Sep. 30, 2022

Marketable Securities [Abstract]

Marketable Securities

Note 10 – Marketable Securities

In January 2022, the Company sold all of its marketable securities in its possession at December 31, 2021 with the original cost $5,988,462. The Company realized $106,324 loss on the sale of these securities and recorded the unrealized gain of $54,508 on its investments in marketable securities for the nine months ended September 30, 2022.

In September 2022, the Company purchased marketable securities at a cost of $2,499,928. The unrealized loss was immaterial for the three and nine months ended September 30, 2022.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11 – Commitments and Contingencies

The Company’s office space lease in Woburn, Massachusetts (the “Woburn Lease”) for the Company’s corporate headquarters was on a month-to-month basis since November 2020 and was terminated in February 2022. The rent expense for this lease was $0 and $52,004 for the three months ended September 30, 2022 and 2021, respectively, and $14,239 and $143,970 for the nine months ended September 30, 2022 and 2021, respectively.

On February 2, 2022, the Company entered into a lease agreement for approximately 15,638 square feet of its new corporate office space in Billerica, Massachusetts (the “Billerica Lease”). The Billerica Lease has a term of 92 months from its effective date and included access to certain additional office space until August 1, 2022. In addition, the Company is required to share in certain taxes and operating expenses of the Billerica Lease.

The Billerica Lease is classified as an operating lease. At the inception date of the Billerica Lease, the Company recorded a right-of-use asset of $1,481,646 in operating lease right-of-use asset, as well as a lease liability of $12,222 in current liabilities and $1,547,614 in long-term liabilities. The operating lease right-of use asset is less than that of the Company’s lease liabilities as of the lease inception date. This is due to the fact that the Company as part of the Billerica Lease was allowed certain tenant improvement allowances, which amounted to $78,190 at lease inception. This lease liability represented the net present value of future lease payments for the lease utilizing a discount rate of 5.98%, which corresponded to the Company’s incremental borrowing rate.

In August 2022, the Company received the tenant improvement allowance from the landlord, which totalled approximately $312,760. This allowance covered the leasehold improvements to the Billerica space and was accounted for as a reduction to the right-of-use asset. As of September 30, 2022, the remaining lease term was 7.1 years.

The Company recorded expense related to the Billerica Lease in the amount of $41,893 and $145,709 for the three-and nine-months ended September 30, 2022, respectively.

During the three and nine months ended September 30, 2022, the Company made cash payments of $7,850 and $45,418, respectively, for amounts included in the measurement of lease liabilities.

The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2022:

2022 (remaining)	$	42,949
2023		197,307
2024		275,875
2025		284,151
Thereafter		1,142,709
Total undiscounted lease liabilities	$	1,942,991
Less effects of discounting		(368,197	)
Total lease liabilities	$	1,574,794

Reported as of September 30, 2022:
Current portion of operating lease liability	$	83,145
Operating lease liability, less current portion		1,491,649
Total lease liabilities	$	1,574,794

Paycheck Protection Program

9 Months Ended

Sep. 30, 2022

Paycheck Protection Program [Abstract]

Paycheck Protection Program

Note 12 — Paycheck Protection Program

On May 5, 2021, the Company applied for and received a loan for $190,100 in connection with the Paycheck Protection Program (“PPP”) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (“CARES”) Act that was signed into law on March 27, 2020.

The loan had a term of 5 years, was unsecured and was guaranteed by the Small Business Administration (“SBA”). The loan bore interest at one percent per annum. Loan payments were to be deferred for borrowers who apply for loan forgiveness until the SBA remits the borrower’s loan forgiveness amount to the lender. If a borrower did not apply for loan forgiveness, payments were to be deferred 10 months after the end of the covered period for the borrower’s loan forgiveness (between 8 and 24 weeks).

Some or all of the loan could be forgiven if at least 75% of the loan proceeds were used by the Company to cover payroll costs, including benefits, and if the Company maintained its employment and compensation within certain parameters during the period following the loan origination date and complied with other relevant conditions.

The Company elected to account for the PPP loan as an in-substance government grant by applying the guidance in International Accounting Standards 20 by analogy based on the assessment that it is probable that it will meet both (a) the eligibility criteria for a PPP loan, and (b) the loan forgiveness criteria for all or substantially all of the PPP loan. Under this guidance, the Company recorded the loan proceeds in other income in the condensed consolidated statement of operations for the three and nine months ended September 30, 2021.

Subsequent Events

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

Subsequent Events

Note 13 — Subsequent Events

On October 13, 2022, the Company’s PPP Loan dated May 5, 2021 was forgiven for the full amount of $190,100 (see Note 12).

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

Investments in marketable securities

Investments in marketable securities

The Company may sell its debt or equity securities in response to changes in interest rates, risk/reward characteristics, liquidity needs or other factors.

Inventory

Inventory

	September 30,		December 31,
	2022		2021

Raw materials	$	118,216	$	91,995
Work in process		128,688		132,160
Total inventory	$	246,904	$	224,155

Stock-based Compensation

Stock-based Compensation

The assumptions used in determining the fair value of share-based awards granted during the nine-months ended September 30, 2022 are as follows:

	September 30, 2022
Risk-free interest rate		1.64	%
Expected option life		6 – 6.1 years
Expected dividend yield		0	%
Expected stock price volatility		54	%

Segments

Segments

The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies.

Leases

Leases

Net Loss per Share

Net Loss per Share

The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:

	September 30,
	2022		2021
Stock options		2,003,919		818,915
Warrants for common stock		4,388,185		4,393,396

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

Recently Issued Accounting Standards

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of Inventory

	September 30,		December 31,
	2022		2021

Raw materials	$	118,216	$	91,995
Work in process		128,688		132,160
Total inventory	$	246,904	$	224,155

Schedule of fair value of share-based awards granted

	September 30, 2022
Risk-free interest rate		1.64	%
Expected option life		6 – 6.1 years
Expected dividend yield		0	%
Expected stock price volatility		54	%

Schedule of net loss per share

	September 30,
	2022		2021
Stock options		2,003,919		818,915
Warrants for common stock		4,388,185		4,393,396

- Definition

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2022

Accrued Liabilities And Other Liabilities [Abstract]

Schedule of accrued expenses

	September 30,		December 31,
	2022		2021

Accrued interest	$	289,633	$	216,073
Other		14,468		95,332
	$	304,101	$	311,405

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of changes in Level 3 liabilities measured at fair value on recurring basis

	Convertible Notes
Balance at December 31, 2020	$	-
Issuance of Amended Notes		3,168,236
Change in fair value of convertible notes		195,962
Fair value of convertible notes at IPO date		(3,364,198	)
Balance at September 30, 2021	$	-

Stock Option Plan (Tables)

9 Months Ended

Sep. 30, 2022

Stock Option Plan [Abstract]

Schedule of stock option activity

	Number of Options		Weighted- Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in Years)
Outstanding as of December 31, 2021		918,919	$	2.09		5.79
Granted		1,085,000	$	1.71
Outstanding of September 30, 2022		2,003,919	$	1.88		7.34
Exercisable at September 30, 2022		919,088	$	2.09		5.04

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of outstanding payables

	September 30, 2022		December 31, 2021

Genomic Diagnostic Technologies	$	-	$	23,725
St. Laurent Institute		232,418		313,679
St. Laurent Realty, Inc.		7,558		27,913
Total related party payables	$	239,976	$	365,317

Common Stock Warrants (Tables)

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Schedule of outstanding warrants to purchase common stock

Issuance Date	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date
8/30/2018		3,088	$	3.10	8/29/2023
9/30/2018		60,506	$	3.10	9/29/2023
9/30/2018		486,486	$	2.16	9/29/2023
10/17/2018		1,157	$	3.10	10/16/2023
11/2/2018		964	$	3.10	11/1/2023
11/9/2018		964	$	3.10	11/8/2023
11/16/2018		964	$	3.10	11/15/2023
11/29/2018		964	$	3.10	11/28/2023
12/21/2018		964	$	3.10	12/20/2023
12/27/2018		964	$	3.10	12/26/2023
1/31/2019		1,930	$	3.10	1/30/2024
2/7/2019		1,640	$	3.10	2/6/2024
2/21/2019		1,640	$	3.10	2/20/2024
3/20/2019		3,378	$	3.10	3/18/2024
4/8/2019		1,930	$	3.10	4/6/2024
11/19/2020		53,333	$	4.10	6/30/2024
11/19/2020		8,533	$	4.10	6/30/2024
1/8/2021		13,333	$	4.10	6/30/2024
1/11/2021		26,666	$	4.10	6/30/2024
2/13/2021		13,333	$	4.10	6/30/2024
3/16/2021		10,665	$	4.10	6/30/2024
3/16/2021		13,333	$	4.10	6/30/2024
8/31/2021		3,519,000	$	4.25	8/31/2026
8/31/2021		153,000	$	4.675	8/26/2026
9/29/2021		9,450	$	4.675	8/26/2026
		4,388,185

Preferred Stock (Tables)

9 Months Ended

Sep. 30, 2022

Preferred Stock [Abstract]

Schedule of outstanding preferred stock

	Shares authorized		Shares issued		Issuance price per share
Series A-1 Convertible Preferred Stock				3,125,000	$	0.32
Series A-2 Convertible Preferred Stock				2,666,665	$	1.68
Series A Preferred stock		20,000,000		5,791,665

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of reconciles undiscounted lease liabilities to the total lease liabilities recognized

2022 (remaining)	$	42,949
2023		197,307
2024		275,875
2025		284,151
Thereafter		1,142,709
Total undiscounted lease liabilities	$	1,942,991
Less effects of discounting		(368,197	)
Total lease liabilities	$	1,574,794

Reported as of September 30, 2022:
Current portion of operating lease liability	$	83,145
Operating lease liability, less current portion		1,491,649
Total lease liabilities	$	1,574,794

Nature of Operations and Basis of Presentation (Details) - USD ($)	1 Months Ended			9 Months Ended
	Jun. 21, 2022	Sep. 29, 2021	Aug. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Apr. 08, 2014
Nature of Operations and Basis of Presentation (Details) [Line Items]
Sale of stock			3,060,000
Gross proceeds (in Dollars)			$ 3,200,000		$ 13,009,621
Cash (in Dollars)			$ 1,600,000
Convertible preferred stock			3,130,622
Outstanding convertible notes			641,895
Purchase of additional shares				459,000
Additional warrants				459,000
Purchase of warrants			459,000
Warrant price per share (in Dollars per share)			$ 0.01
Company issued of shares		189,000
Underwriters price per share (in Dollars per share)		$ 4.24
Net proceeds (in Dollars)		$ 730,000
Common stock per share (in Dollars per share)	$ 1
Notice from the Nasdaq stock market, description				The Preferred Stock was subject to automatic conversion upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred Stock voting together as a single class. In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock, upon the consent of the holders of a majority of the Preferred Stock, automatically converted into 3,130,622 shares of common stock.
Warrant [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Common stock exercise price (in Dollars per share)			4.25
Public price per share (in Dollars per share)			$ 4.25
Minimum [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Common stock per share (in Dollars per share)	$ 1
SeqLL, LLC [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Ownership interest, percentage						100.00%
Initial Public Offering [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Gross proceeds (in Dollars)			$ 13,000,000
SeqLL, LLC [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Notice from the Nasdaq stock market, description	To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days.
Maxim Group LLC [Member]
Nature of Operations and Basis of Presentation (Details) [Line Items]
Warrants issued (in Dollars)			$ 1,600,000

Significant Accounting Policies (Details)	9 Months Ended
Significant Accounting Policies (Details)	Sep. 30, 2022
Accounting Policies [Abstract]
Employees contractual term	10 years

Significant Accounting Policies (Details) - Schedule of inventory - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Inventory Abstract
Raw materials	$ 118,216	$ 91,995
Work in process	128,688	132,160
Total inventory	$ 246,904	$ 224,155

Significant Accounting Policies (Details) - Schedule of fair value of share-based awards granted	9 Months Ended
	Sep. 30, 2022
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Risk-free interest rate	1.64%
Expected dividend yield	0.00%
Expected stock price volatility	54.00%
Minimum [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Expected option life	6 years
Maximum [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Expected option life	6 years 1 month 6 days

Significant Accounting Policies (Details) - Schedule of net loss per share - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock options [Member]
Significant Accounting Policies (Details) - Schedule of net loss per share [Line Items]
Diluted net loss per share	2,003,919	818,915
Warrants for common stock [Member]
Significant Accounting Policies (Details) - Schedule of net loss per share [Line Items]
Diluted net loss per share	4,388,185	4,393,396

Accrued Expenses (Details) - Schedule of accrued expenses - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Accrued Expenses Abstract
Accrued interest	$ 289,633	$ 216,073
Other	14,468	95,332
Accrued expenses, total	$ 304,101	$ 311,405

Fair Value Measurements (Details) - USD ($)	9 Months Ended
Fair Value Measurements (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value Measurements (Details) [Line Items]
Investments	$ 4,002,061
Cash and cash equivalents	$ 1,502,376	$ 60,021
Common stock shares (in Shares)	641,895
Change in fair value of notes	$ 89,239
Investments in Mutual Funds [Member]
Fair Value Measurements (Details) [Line Items]
Investments		$ 5,993,385

Fair Value Measurements (Details) - Schedule of changes in Level 3 liabilities measured at fair value on recurring basis - Convertible Note [Member]	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning
Issuance of Amended Notes	3,168,236
Change in fair value of convertible notes	195,962
Fair value of convertible notes at IPO date	(3,364,198)
Balance at ending

Stock Option Plan (Details) - USD ($)	3 Months Ended		9 Months Ended
Stock Option Plan (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock Option Plan (Details) [Line Items]
Available for future issuance of shares (in Shares)	1,496,081		1,496,081
Option excess, term			10 years
Weighted average grant date fair value of options (in Dollars per share)			$ 0.89
Stock-based compensation	$ 66,996	$ 214,745	$ 189,905	$ 218,944
General and administrative expenses	46,394	214,745	131,533	218,944
Research and development expenses	$ 20,602	$ 0	58,372	$ 0
Unrecognized compensation expense			$ 777,808
Weighted average period term			1 year 7 months 13 days
Minimum [Member]
Stock Option Plan (Details) [Line Items]
Grant and vest period, term			3 years
Maximum [Member]
Stock Option Plan (Details) [Line Items]
Grant and vest period, term			4 years
2014 Equity Incentive Plan [Member]
Stock Option Plan (Details) [Line Items]
Grant of options (in Shares)			3,500,000

Stock Option Plan (Details) - Schedule of stock option activity	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Schedule Of Stock Option Activity Abstract
Number of Options, Outstanding as of beginning balance \| shares	918,919
Weighted- Average Exercise Price per Share, Outstanding as of beginning balance \| $ / shares	$ 2.09
Weighted Average Remaining Contractual Term (in Years), Outstanding as of beginning balance	5 years 9 months 14 days
Number of Options, Granted \| shares	1,085,000
Weighted- Average Exercise Price per Share, Granted \| $ / shares	$ 1.71
Number of Options, Outstanding of ending balance \| shares	2,003,919
Weighted- Average Exercise Price per Share, Outstanding of ending balance \| $ / shares	$ 1.88
Weighted Average Remaining Contractual Term (in Years), Outstanding of ending balance	7 years 4 months 2 days
Number of Options, Exercisable \| shares	919,088
Weighted- Average Exercise Price per Share, Exercisable \| $ / shares	$ 2.09
Weighted Average Remaining Contractual Term (in Years), Exercisable	5 years 14 days

Related Party Transactions (Details) - Schedule of outstanding payables - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Total related party payables	$ 239,976	$ 365,317
Genomic Diagnostic Technologies [Member]
Related Party Transaction [Line Items]
Total related party payables		23,725
St. Laurent Institute [Member]
Related Party Transaction [Line Items]
Total related party payables	232,418	313,679
St. Laurent Realty, Inc. [Member]
Related Party Transaction [Line Items]
Total related party payables	$ 7,558	$ 27,913

- Definition

Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

+ Details

Notes Payable (Details) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended	9 Months Ended
Notes Payable (Details) - USD ($)	Mar. 31, 2021	Feb. 03, 2021	Oct. 31, 2021	Apr. 29, 2021	Dec. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Oct. 01, 2021	Sep. 30, 2020	Apr. 29, 2020	Apr. 08, 2019
Notes Payable (Details) [Line Items]
Preferred stockholder value															$ 1,375,000
Accrued interest rate						10.00%			10.00%
Convertible per share (in Dollars per share)						$ 3.75			$ 3.75
Third-party investor amount					$ 200,000
Promissory notes accrue interest						10.00%			10.00%
Repaid date									Dec. 31, 2022
Issuance of equity offering							$ 71,199		$ 7,500,000
Non-convertible					$ 426,020
Due date					Jul. 31, 2022
Non-convertible interest					10.00%
Total investors											$ 250,000
Number of common shares percentage									10.00%
Maturity date								Jul. 31, 2024	Dec. 31, 2022
Issuable to conversion shares (in Shares)									7.5
Convertible exercise price per share (in Dollars per share)									$ 3.75
Convertible promissory note granted		$ 2,910,710
Additional outstanding	$ 786,730			$ 50,000
Conversion prices increase (in Dollars per share)	$ 3.75
Conversion prices decrease (in Dollars per share)	$ 3.1
Extinguishment of debt	$ 934,257
Fair value	3,118,235					$ 3,364,198			$ 3,364,198
Carrying value	2,183,978
Convertible original terms shares (in Shares)									641,895
Cash payments									$ 141,884
Convertible notes									$ 195,962
Accounting loss			$ 1,375,000
Promissory notes repaid			$ 270,000
Total purchase (in Shares)							66,665			66,665				53,333
Placement agent (in Shares)						11,466			11,466
Promissory note								$ 1,375,000
Interest expense						$ 17,188	$ 41,066		$ 73,560	$ 189,993
Minimum [Member]
Notes Payable (Details) [Line Items]
Conversion agreements	826,020
Promissory note rate													5.00%
Maximum [Member]
Notes Payable (Details) [Line Items]
Conversion agreements	1,265,710
Promissory note rate													10.00%
IPO [Member]
Notes Payable (Details) [Line Items]
Common stock value	1,552,683
Conversion price (in Dollars per share)				$ 3.75
Convertible Notes Payable [Member]
Notes Payable (Details) [Line Items]
Preferred stockholder value																$ 905,000
Accrued interest rate						10.00%			10.00%
Convertible per share (in Dollars per share)						$ 3.1			$ 3.1
Convertible discount rate									20.00%
Additional outstanding	$ 1,305,000

Common Stock Warrants (Details)	9 Months Ended
Common Stock Warrants (Details)	Sep. 30, 2022 USD ($) $ / shares
Stockholders' Equity Note [Abstract]
Warrants amount \| $	$ 5,211
Warrants exercise price \| $ / shares	$ 3.1

Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase common stock	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Total	4,388,185
8/30/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 30, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	3,088
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Aug. 29, 2023
9/30/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Sep. 30, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	60,506
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Sep. 29, 2023
9/30/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Sep. 30, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	486,486
Exercise Price \| $ / shares	$ 2.16
Expiration Date	Sep. 29, 2023
10/17/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Oct. 17, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	1,157
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Oct. 16, 2023
11/2/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 02, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	964
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Nov. 01, 2023
11/9/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 09, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	964
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Nov. 08, 2023
11/16/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 16, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	964
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Nov. 15, 2023
11/29/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 29, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	964
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Nov. 28, 2023
12/21/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 21, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	964
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Dec. 20, 2023
12/27/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 27, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	964
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Dec. 26, 2023
1/31/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Jan. 31, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	1,930
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Jan. 30, 2024
2/7/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 07, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	1,640
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Feb. 06, 2024
2/21/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 21, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	1,640
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Feb. 20, 2024
3/20/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 20, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	3,378
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Mar. 18, 2024
4/8/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Apr. 08, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	1,930
Exercise Price \| $ / shares	$ 3.1
Expiration Date	Apr. 06, 2024
11/19/2020 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 19, 2020
Number of Shares Issuable Upon Exercise of Outstanding Warrants	53,333
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
11/19/2020 One [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 19, 2020
Number of Shares Issuable Upon Exercise of Outstanding Warrants	8,533
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
1/8/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Jan. 08, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	13,333
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
1/11/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Jan. 11, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	26,666
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
2/13/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 13, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	13,333
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
3/16/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 16, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	10,665
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
3/16/2021 One [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 16, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	13,333
Exercise Price \| $ / shares	$ 4.1
Expiration Date	Jun. 30, 2024
8/31/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 31, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	3,519,000
Exercise Price \| $ / shares	$ 4.25
Expiration Date	Aug. 31, 2026
8/31/2021 One [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 31, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	153,000
Exercise Price \| $ / shares	$ 4.675
Expiration Date	Aug. 26, 2026
9/29/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Sep. 29, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	9,450
Exercise Price \| $ / shares	$ 4.675
Expiration Date	Aug. 26, 2026

Preferred Stock (Details)	9 Months Ended
Preferred Stock (Details)	Sep. 30, 2022 $ / shares
Preferred Stock (Details) [Line Items]
Conversion of preferred stock, description	The Preferred Stock was subject to automatic conversion upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred Stock voting together as a single class. In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock, upon the consent of the holders of a majority of the Preferred Stock, automatically converted into 3,130,622 shares of common stock.
Series A-1 [Member]
Preferred Stock (Details) [Line Items]
Original issue price per share	$ 0.59
Conversion price per share	0.59
Series A-2 [Member]
Preferred Stock (Details) [Line Items]
Original issue price per share	3.1
Conversion price per share	$ 3.1

Preferred Stock (Details) - Schedule of outstanding preferred stock	Dec. 31, 2020 $ / shares shares
Series A-1 Convertible Preferred Stock [Member]
Conversion of Stock [Line Items]
Shares issued	3,125,000
Issuance price per share (in Dollars per share) \| $ / shares	$ 0.32
Series A-2 Convertible Preferred Stock [Member]
Conversion of Stock [Line Items]
Shares issued	2,666,665
Issuance price per share (in Dollars per share) \| $ / shares	$ 1.68
Series A Preferred Stock [Member]
Conversion of Stock [Line Items]
Shares authorized	20,000,000
Shares issued	5,791,665

Marketable Securities (Details) - USD ($)	9 Months Ended
Marketable Securities (Details) - USD ($)	Sep. 30, 2022	Jan. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable securities cost	$ 2,499,928	$ 5,988,462
Loss on sale of securities	106,324
Unrealized gain	$ 54,508

Commitments and Contingencies (Details)		3 Months Ended		9 Months Ended
Commitments and Contingencies (Details)	Feb. 02, 2022 m²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Rent expense for lease		$ 0	$ 52,004	$ 14,239	$ 143,970
Office space (in Square Meters) \| m²	15,638
Lease term	92 months
Operating lease right-of-use asset				1,481,646
Lease liability		12,222		12,222
Long-term liabilities		1,547,614		1,547,614
Lease inception		78,190		$ 78,190
Lease utilizing a discount rate				5.98%
Land improvement		$ 312,760		$ 312,760
Remaining lease term		7 years 1 month 6 days		7 years 1 month 6 days
Lease expense		$ 41,893		$ 145,709
Cash payments		$ 7,850		$ 45,418

Commitments and Contingencies (Details) - Schedule of reconciles undiscounted lease liabilities to the total lease liabilities recognized	Sep. 30, 2022 USD ($)
Schedule Of Reconciles Undiscounted Lease Liabilities To The Total Lease Liabilities Recognized Abstract
2022 (remaining)	$ 42,949
2023	197,307
2024	275,875
2025	284,151
Thereafter	1,142,709
Total undiscounted lease liabilities	1,942,991
Less effects of discounting	(368,197)
Total lease liabilities	1,574,794
Reported as of September 30, 2022:
Current portion of operating lease liability	83,145
Operating lease liability, less current portion	1,491,649
Total lease liabilities	$ 1,574,794

Paycheck Protection Program (Details) - USD ($)	9 Months Ended
Paycheck Protection Program (Details) - USD ($)	Sep. 30, 2022	May 05, 2021
Paycheck Protection Program [Abstract]
Loan received (in Dollars)		$ 190,100
Loan term	5 years
Percentage of interest	1.00%
Forgiven loan proceeds percentage	75.00%

Subsequent Events (Details)	Oct. 13, 2022 USD ($)
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
PPP Loan amount	$ 190,100